GSA Capital Partners LLP Boosts Stock Position in OPKO Health, Inc. (NASDAQ:OPK)

Key Points

• GSA Capital Partners LLP increased its holdings in OPKO Health by 24.2%, owning approximately 1.34 million shares valued at $2.23 million.
• The company reported a loss of $0.10 EPS for the quarter, missing analysts' expectations, as revenue dropped 13.7% year-over-year.
• Several analysts have varying ratings on the stock, with average target price set at $2.75, indicating a general outlook of a "Moderate Buy."

GSA Capital Partners LLP boosted its holdings in shares of OPKO Health, Inc. (NASDAQ:OPK - Free Report) by 24.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,343,701 shares of the biotechnology company's stock after buying an additional 261,495 shares during the quarter. GSA Capital Partners LLP owned approximately 0.17% of OPKO Health worth $2,231,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Oak Thistle LLC purchased a new stake in shares of OPKO Health in the first quarter worth about $26,000. Cerity Partners LLC purchased a new position in shares of OPKO Health during the 1st quarter worth about $36,000. Pallas Capital Advisors LLC purchased a new position in shares of OPKO Health during the 1st quarter worth about $43,000. Wealth Enhancement Advisory Services LLC boosted its stake in shares of OPKO Health by 75.3% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company's stock worth $42,000 after purchasing an additional 12,417 shares during the period. Finally, Zacks Investment Management purchased a new position in shares of OPKO Health during the 4th quarter worth about $49,000. 64.63% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently commented on OPK. Wall Street Zen cut shares of OPKO Health from a "hold" rating to a "sell" rating in a report on Monday, May 5th. Barrington Research restated an "outperform" rating and issued a $2.25 price target on shares of OPKO Health in a report on Thursday, May 1st. JPMorgan Chase & Co. began coverage on shares of OPKO Health in a report on Friday, April 25th. They issued a "neutral" rating on the stock. HC Wainwright restated a "buy" rating and issued a $3.00 price target on shares of OPKO Health in a report on Monday, April 7th. Finally, LADENBURG THALM/SH SH upgraded shares of OPKO Health to a "strong-buy" rating in a report on Tuesday, July 8th. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, OPKO Health presently has an average rating of "Moderate Buy" and an average target price of $2.75.

OPKO Health Stock Down 7.4%

Shares of OPK traded down $0.10 during midday trading on Friday, hitting $1.19. 6,411,007 shares of the company's stock traded hands, compared to its average volume of 3,923,068. OPKO Health, Inc. has a 1 year low of $1.11 and a 1 year high of $2.04. The firm's fifty day moving average is $1.34 and its 200-day moving average is $1.48. The company has a current ratio of 2.49, a quick ratio of 2.28 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $939.76 million, a price-to-earnings ratio of -16.93 and a beta of 1.34.

OPKO Health (NASDAQ:OPK - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The biotechnology company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.07). OPKO Health had a negative net margin of 5.66% and a negative return on equity of 2.85%. The business had revenue of $156.80 million for the quarter, compared to analysts' expectations of $165.74 million. During the same quarter in the prior year, the company posted ($0.01) EPS. The business's revenue for the quarter was down 13.9% on a year-over-year basis. As a group, sell-side analysts anticipate that OPKO Health, Inc. will post -0.25 earnings per share for the current year.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.